Ala’a E. Shurrab
University of Salford
9 Papers
59 Citations
Ala’a E. Shurrab is an academic researcher from University of Salford. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 8, co-authored 9 publications. Previous affiliations of Ala’a E. Shurrab include Salford Royal NHS Foundation Trust.
Chat about Author
Papers
Measurement of single kidney function using dynamic contrast-enhanced MRI: comparison of two models in human subjects.
TL;DR: Two methods for assessing the single kidney glomerular filtration rate (SK‐GFR) in humans using dynamic contrast‐enhanced (DCE)‐MRI are compared.
138
MR-derived renal morphology and renal function in patients with atherosclerotic renovascular disease.
Ching M. Cheung,Ala’a E. Shurrab,David L. Buckley,Janet Hegarty,Rachel J. Middleton,Hari Mamtora,Philip A. Kalra +6 more
TL;DR: 3D parameters of parenchymal volume are stronger correlates of isoSK-GFR than two-dimensional measures of BL, PT or CT, and may represent a subgroup with the potential to respond beneficially to angioplasty.
59
Progression of cardiac dysfunction in patients with atherosclerotic renovascular disease.
TL;DR: Patients with ARVD exhibit a high prevalence of LVH at diagnosis and progressive left ventricular dilatation over the first year after diagnosis and an association between elevated time-averaged PTH and LV dilatations is revealed.
38
Increasing the diagnostic yield of renal angiography for the diagnosis of atheromatous renovascular disease.
TL;DR: The criteria for angiography is to be rationalized in the light of these findings, anticipating an increase in the diagnostic yield of renal angiographic study from its current 33.3% to above 42%.
23
Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis
TL;DR: Rituximab appears an effective and safe treatment choice for the induction of remission in severe AASV that is not responding to standard agents, at the initial presentation and for maintenance therapy, without the development of common serious side-effects associated with immunosuppression.
9